WuXi STA has begun construction of a new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, in the United States.
This location will be WuXi STA's second in the country, providing increased flexibility and capacity to meet the demands of clients in the U.S. and beyond.
The WuXi STA Middletown location, the company's first building, is situated in the Middletown Business Center at 1091 Industrial Drive.
By 2026, the new state-of-the-art facility will have employed 500 people full-time.
A variety of oral and injectable dosage forms will be offered at Phase I of the new campus, as well as clinical and commercial drug product manufacturing services, including packaging, labeling, storing, and distributing clinical trial materials and commercial drug products.
With 12 locations in the United States, Europe, and Asia, WuXi STA provides a variety of services and complies with all legal requirements.
This new facility will further improve the company's global drug production capacity and capabilities, along with three existing drug product manufacturing locations in Couvet (Switzerland), Wuxi City (China), and Shanghai (China).
Operations at the WuXi STA Middletown facility are anticipated to start in 2025.